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News: Astra Zeneca closing its Neuroscience 
R&D. According to the news1: “Hit with slid-
ing profits, a weak late-stage pipeline, and 
a troubling track record on clinical trials, 
AstraZeneca (AZN) has decided to trigger 
another round of layoffs, with 2,200 R&D 
staffers losing their jobs in this round. Part 
of a broader reorganization that will elimi-
nate 7,300 jobs, AstraZeneca says that it is 
cutting way back on neuroscience, reduc-
ing the number of investigators it has in 
the field to a mere 40 or 50 in Boston and 
Cambridge, UK as it creates a new ‘virtual’ 
group which will collaborate with academic 
and industry partners around the world.”
While AZN was not heavily involved 
or even involved at all in R&D for TBI, 
the news is important and alerting since 
it further illustrates the trend that started 
last year or so. As the news continues: 
“AstraZeneca is joining a major exodus 
out of brain disorders, a tough field where 
scientists face extraordinarily high risks in 
the clinic and an imperfect understanding 
of many of the diseases. GlaxoSmithKline 
(GSK) and Sanofi (SNY) led the exit 
with Merck (MRK) cutting back as well. 
Alzheimer’s, Parkinson’s, and other condi-
tions affect huge patient populations, rais-
ing the prospect that any pharmaceutical 
advances would swiftly be rewarded with 
blockbuster returns. Increasingly, though, 
the fear of high-profile clinical failures has 
won out over the search for big new drugs 
in the field, triggering deep worries among 
patient advocacy groups.”
There is a productivity crisis in phar-
maceutical R&D in general (e.g., Pammolli 
et al., 2011). Among the main reasons, 
attrition rates across all categories have 
been increasing especially in Phase II and 
Phase III (the most costly) of clinical trials. 
Between 1990 and 2004, attrition rates in 
Phase III has more than doubled across the 
board, from around 20% in 1900 to more 
than 50% in 2004. Pharmaceutical compa-
nies, like other businesses, have a primary 
responsibility toward their shareholders. 
(As it was posted at Intel, the number 
one semiconductor company: “We are in 
the business of making money”; Jackson, 
1998). The combination of factors such as 
patent expirations, constrained health care 
budgets in virtually all developed countries 
coupled with increasingly stringent regu-
latory requirements and the skyrocketing 
costs of R&D have been forcing pharma-
ceuticals to cut their losses. Sadly, neuro-
science R&D for reasons, some discussed 
above, is the logical and rational choice. So, 
what’s the new model for pharmaceutical 
R&D in neuroscience? As AZN has outlined 
it: “We have made an active choice to stay 
in neuroscience though we will work very 
differently to share cost, risk, and reward 
with partners in this especially challenging 
but important field of medical research,” 
says Martin Mackay, the company’s R&D 
chief. “The creation of a virtual neurosci-
ence iMed will make us more agile scien-
tifically and financially – we will be able to 
collaborate flexibly with the best scientific 
expertise, wherever it exists in the world.” In 
the absence of “brick and mortar” R&D at 
AZN (and at other pharmaceuticals), there 
will likely be only “virtual neuroscience” as 
AZN’s Mackay indicated. Likely, the model 
also means “virtual funding” for neurosci-
ence R&D.
Based on available data, pharmaceutical 
R&D accounted for roughly 50% of fund-
ing sources for neuroscience research (in 
the US) between 1995 and 2005 (Dorsey 
et al., 2006). The figures are similar in the 
EU (and likely also in Japan and the Asia 
Pacific region). When pharmaceutical 
companies drastically cut back on neu-
roscience R&D and NIH (or similar EU 
and Japanese) organizations are not able 
to fill the gap, there can be a substantial, 
50% deficit in neuroscience R&D funding. 
The unfortunate reality is TBI research has 
never received much support from the NIH 
or pharmaceutical companies. Funding for 
TBI research has been disproportional to 
the prevalence of the disease and also to its 
cumulative human and financial costs to 
societies.
Academic TBI research may have 
also contributed to the current crisis. 
Pharmaceutical companies have com-
monly based their own R&D efforts on 
data derived from academic research. When 
published results were not reproducible or 
were attainable only under specific circum-
stances they are useless for continuing the 
R&D process toward drug development. If 
the company was lucky, these were “early 
failures.” Many, too many promising “low 
hanging fruits” identified by academic TBI 
research turned out to be-just like in the 
real orchard – looking great but not ready 
for consumption.
In the light of the mass exodus of phar-
maceuticals from neuroscience R&D, we 
are especially concerned about the future 
of R&D for TBI. Where will the new medi-
cations treating sufferers of TBI be com-
ing from? Since pharmaceutical companies 
appear reluctant to invest money in R&D 
for drugs for Alzheimer’s and Parkinson’s 
Disease and multiple sclerosis claiming 
complexity, it seems unlikely that TBI, one 
of the most complex CNS disorders, would 
be prioritized.
So how does the near future of R&D for 
TBI look today? Unfortunately, not bright. 
However, we believe that after surviving the 
current “strategic inflection point” (Grove, 
1999) by adjusting, pharmaceutical compa-
nies will (re)discover the market for neurosci-
ence including TBI drugs representing huge 
unmet needs. The similar “strategic inflec-
tion point” is likely reaching the academia, 
and TBI research in the academia also needs 
to adjust. We believe that this crisis brings 
about unique opportunities for the TBI 
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of the FDA Critical Path Initiative) since its 
inception in 2004 has been working hard to 
bring the major players-industry, academia, 
and regulatory agencies together in order 
to accelerate the development of safe drugs 
for various diseases (Woosley et al., 2010). 
(Unfortunately, TBI is not on the list.)
We believe pharmaceutical companies 
will come back to invest in R&D for neu-
roscience including TBI. They will do it 
when the conditions are right, the major 
stars are aligned; the regulatory agencies 
will have created the right conditions and 
funding agencies the innovative funding 
mechanism; the academic world will have 
learned to use the money more wisely and 
creatively; and will have implemented the 
“open source” model. When pharmaceutical 
companies will be back, they can expect very 
substantial returns on their investments. 
And after all, it is for the money they are 
in the business. Most importantly, TBI 
patients will also tremendously profit.
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more translational and clinical. Academic 
and also industrial R&D in TBI can be far 
more productive through bringing clini-
cal and experimental researchers together 
working in cooperative and correlated fash-
ion (Agoston et al., 2012). Agreeably, we 
only have an incomplete understanding of 
the biology of CNS and its diseases, we do 
not have the ability to define and measure 
outcomes, we lack perfect biomarkers, etc. 
However, we have not been able even to 
figure out how to put the existing infor-
mation together in order to generate new 
knowledge and to identify real gaps. It is 
astonishing how little available advanced 
information technology has been used in 
neuroscience and especially in TBI R&D. 
They transform our every day lives but 
when we enter the lab, the clinic, office, 
they mostly stay outside. Using the power of 
information technologies to generate new 
understanding and knowledge from exist-
ing but fragmented information in neu-
roscience is a challenge worst for Google’s 
“Solve for X” Project intended to tackle Big 
Problems2. Computer modeling connecting 
the physics and the biology of TBI can gen-
erate a completely new level of knowledge 
enabling among others a more efficient and 
ethical way of performing experiments and 
clinical studies. Information technology 
can also transform TBI research by creat-
ing advanced patient registers, databases 
for designing, and assessing clinical tri-
als that will attract pharmaceuticals. One 
of the most effective ways to understand 
TBI, the disease, would probably be to per-
form a multicenter comparative effective-
ness study. Using informatics tools, such a 
study can relatively quickly provide criti-
cal missing information about this com-
plex disease. The value of such a study can 
be increased substantially by incorporat-
ing data from relevant experimental TBI 
studies using established criteria (Agoston 
et al., 2012). Large pharmaceutical compa-
nies present in many countries each with 
different models of healthcare and TBI 
treatment practices can play a major role 
in such studies by designing, coordinat-
ing (and also financing) such studies. In 
the US, the NIH has recognized the value 
of translational research and started to 
increase funding for it (Mullard, 2004). 
community, funding and regulatory agen-
cies, academia, pharmaceuticals, and biotech 
companies to change their models. Probably 
NIH and other funding agencies can make 
the largest impact in neuroscience and TBI 
R&D by fine-tuning their current models 
to finance TBI research. NIH already has a 
mechanism to fund small and also startup 
businesses, biotech companies, and others. At 
the expense of large center grants, these more 
agile entities and also small academic groups 
should receive more funding. These organi-
zations would be more willing and more 
forced to “think outside of the box.” They 
will also be the natural partners – and small 
biotech companies are also natural targets for 
acquisitions – of big pharmaceuticals. Small 
biotech companies can provide innovative 
drug candidates, but a sustainable involve-
ment of large experienced pharmaceutical 
companies is probably required in order to 
achieve a really effective development of new 
drugs. The large established companies have 
the resources to make the critical changes in 
ligands to refine receptor binding and to per-
form the clinical trials.
Regulatory agencies, including govern-
ments should create the framework for 
innovation and accumulating and retain-
ing knowledge. Whichever country will 
establish easy, non-bureaucratic regulatory 
environment that is actively encouraging, 
nourishing, and supporting innovation, 
will attract neuroscience R&D (back). 
Remember the “iMed” concept by AZN? 
Pharmaceuticals are scouting for talent and 
opportunity globally.
Part of the new model adopted by phar-
maceutical companies already includes 
collaborative alliances, shared precompeti-
tive research (FitzGerald, 2010; Woodcock, 
2010). Can these new models also be imple-
mented in both experimental and clinical TBI 
research performed in the academia? Unless 
funding agencies, e.g., NIH will motivate (or 
enforce) sharing resources and information 
academic research will most certainly keep 
its current (fragmented) model. When how-
ever academia will have started to practice 
resource and data sharing (“open source”) 
it will be able to provide truly novel insights 
into pathological mechanisms that would be 
the targets for new drugs in TBI along with 
more useful models for preclinical trials.
Likely, after the current “creative destruc-
tion” the face of neuroscience R&D includ-
ing TBI will however change. It will be 
2http://www.zdnet.com/blog/google/solve-for-x-goo-
gle-gathers-top-minds-to-solve-everything/3569
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